These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19393834)

  • 21. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
    Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
    Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
    Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
    Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaplastic lymphoma kinase proteins in growth control and cancer.
    Pulford K; Morris SW; Turturro F
    J Cell Physiol; 2004 Jun; 199(3):330-58. PubMed ID: 15095281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F; Arnold MD; Frist AY; Pulford K
    Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic mutations of ALK kinase in neuroblastoma.
    Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
    Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ALK signaling for cancer therapy.
    Mossé YP; Wood A; Maris JM
    Clin Cancer Res; 2009 Sep; 15(18):5609-14. PubMed ID: 19737948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
    Lamant L; Gascoyne RD; Duplantier MM; Armstrong F; Raghab A; Chhanabhai M; Rajcan-Separovic E; Raghab J; Delsol G; Espinos E
    Genes Chromosomes Cancer; 2003 Aug; 37(4):427-32. PubMed ID: 12800156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
    Herbst H; Sander C; Tronnier M; Kutzner H; Hügel H; Kaudewitz P
    Br J Dermatol; 1997 Nov; 137(5):680-6. PubMed ID: 9415224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
    Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
    Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
    Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
    Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.
    Li R; Xue L; Zhu T; Jiang Q; Cui X; Yan Z; McGee D; Wang J; Gantla VR; Pickens JC; McGrath D; Chucholowski A; Morris SW; Webb TR
    J Med Chem; 2006 Feb; 49(3):1006-15. PubMed ID: 16451066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
    Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
    Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
    Bossi RT; Saccardo MB; Ardini E; Menichincheri M; Rusconi L; Magnaghi P; Orsini P; Avanzi N; Borgia AL; Nesi M; Bandiera T; Fogliatto G; Bertrand JA
    Biochemistry; 2010 Aug; 49(32):6813-25. PubMed ID: 20695522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase.
    Gunby RH; Tartari CJ; Porchia F; Donella-Deana A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2005 Jul; 90(7):988-90. PubMed ID: 15996942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK inhibitors in lung cancer.
    Heath E
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):649-50. PubMed ID: 20040904
    [No Abstract]   [Full Text] [Related]  

  • 40. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
    McDermott U; Sharma SV; Dowell L; Greninger P; Montagut C; Lamb J; Archibald H; Raudales R; Tam A; Lee D; Rothenberg SM; Supko JG; Sordella R; Ulkus LE; Iafrate AJ; Maheswaran S; Njauw CN; Tsao H; Drew L; Hanke JH; Ma XJ; Erlander MG; Gray NS; Haber DA; Settleman J
    Proc Natl Acad Sci U S A; 2007 Dec; 104(50):19936-41. PubMed ID: 18077425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.